AZD-1480
Cat.No:IA1630 Solarbio
CAS:935666-88-9
Molecular Formula:C14H14ClFN8
Molecular Weight:348.77
Storage:Powder:2-8℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year
Purity:≥98%
Appearance:Solid
Qty:
Size:
{{cart_num}}
My Cart> Small Molecule Compounds > Inhibitors & Antagonists & Agonists > JAK/STAT > AZD-1480CAS:935666-88-9
Molecular Formula:C14H14ClFN8
Molecular Weight:348.77
Storage:Powder:2-8℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year
Purity:≥98%
Appearance:Solid
Qty:
Size:
| CAS | 935666-88-9 |
| Name | AZD-1480 |
| Molecular Formula | C14H14ClFN8 |
| Molecular Weight | 348.77 |
| Solubility | Soluble in DMSO |
| Purity | ≥98% |
| Appearance | Solid |
| Storage | Powder:2-8℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year |
| Delivery Time | 1-2 Days |
| MDL | MFCD16038904 |
| SMILES | ClC1=C(N=C(N=C1)N[C@@H](C)C2=NC=C(C=N2)F)NC3=NNC(C)=C3 |
| InChIKey | PDOQBOJDRPLBQU-QMMMGPOBSA-N |
| InChI | InChI=1S/C14H14ClFN8/c1-7-3-11(24-23-7)21-13-10(15)6-19-14(22-13)20-8(2)12-17-4-9(16)5-18-12/h3-6,8H,1-2H3,(H3,19,20,21,22,23,24)/t8-/m0/s1 |
| PubChem CID | 16659841 |
| Target Point | JAK |
| Passage | JAK/STAT Signaling |
| Background | AZD-1480 is a novel ATP-competitive inhibitor of JAK2 |
| Biological Activity | AZD-1480 是一种新颖的 JAK2 的ATP竞争性抑制剂,IC50 值为 < 0.4 nM[1-6]。 |
| IC50 | JAK1:1.3nM;JAK2:0.4nM [1-6] |
| Data Literature Source | [1]. Derenzini E,et al. The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma. Blood Cancer J. 2011 Dec;1(12):e46. [2]. Scuto A,et al. The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling,resulting in suppression of human myeloma cell growth and survival. Leukemia. 2011 Mar;25(3):538-50. [3]. McFarland BC,et al. Therapeutic potential of AZD1480 for the treatment of human glioblastoma. Mol Cancer Ther. 2011 Dec;10(12):2384-93. [4]. Xin H,et al. Antiangiogenic and antimetastatic activity of JAK inhibitor AZD1480. Cancer Res. 2011 Nov 1;71(21):6601-10. [5]. Hedvat M,et al. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell. 2009 Dec 8;16(6):487-9 [6]. Ni J,et al. Tyrosine receptor kinase B is a drug target in astrocytomas. Neuro Oncol. 2017 Jan;19(1):22-30. |
| Unit | Bottle |
| Specification | 5mg 10mg |
Remark:These protocols are for reference only. Solarbio does not independently validate these methods.
Note:
1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.
3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.
Sorry, there is no more information.
Sorry, there is no more information.
Manual Download